全文获取类型
收费全文 | 306648篇 |
免费 | 27697篇 |
国内免费 | 18313篇 |
专业分类
耳鼻咽喉 | 2752篇 |
儿科学 | 4140篇 |
妇产科学 | 5351篇 |
基础医学 | 34004篇 |
口腔科学 | 5268篇 |
临床医学 | 39272篇 |
内科学 | 46856篇 |
皮肤病学 | 3519篇 |
神经病学 | 15866篇 |
特种医学 | 10987篇 |
外国民族医学 | 118篇 |
外科学 | 32396篇 |
综合类 | 49329篇 |
现状与发展 | 62篇 |
一般理论 | 55篇 |
预防医学 | 21469篇 |
眼科学 | 8188篇 |
药学 | 31644篇 |
266篇 | |
中国医学 | 16435篇 |
肿瘤学 | 24681篇 |
出版年
2024年 | 807篇 |
2023年 | 3979篇 |
2022年 | 9454篇 |
2021年 | 14318篇 |
2020年 | 10789篇 |
2019年 | 9359篇 |
2018年 | 9827篇 |
2017年 | 9158篇 |
2016年 | 8542篇 |
2015年 | 13014篇 |
2014年 | 16617篇 |
2013年 | 16135篇 |
2012年 | 23445篇 |
2011年 | 25635篇 |
2010年 | 16877篇 |
2009年 | 13649篇 |
2008年 | 17339篇 |
2007年 | 17339篇 |
2006年 | 16495篇 |
2005年 | 15893篇 |
2004年 | 11117篇 |
2003年 | 9994篇 |
2002年 | 8593篇 |
2001年 | 7517篇 |
2000年 | 7151篇 |
1999年 | 7029篇 |
1998年 | 3937篇 |
1997年 | 3988篇 |
1996年 | 3013篇 |
1995年 | 2756篇 |
1994年 | 2376篇 |
1993年 | 1603篇 |
1992年 | 2378篇 |
1991年 | 2077篇 |
1990年 | 1740篇 |
1989年 | 1531篇 |
1988年 | 1308篇 |
1987年 | 1192篇 |
1986年 | 969篇 |
1985年 | 781篇 |
1984年 | 509篇 |
1983年 | 402篇 |
1982年 | 237篇 |
1981年 | 212篇 |
1980年 | 198篇 |
1979年 | 261篇 |
1978年 | 151篇 |
1977年 | 122篇 |
1976年 | 102篇 |
1974年 | 119篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
141.
142.
天麻素是从兰科植物天麻的块茎中提取分离而得,现已人工合成。天麻素药理作用广泛,如镇痛、镇静安眠、促智、保护神经元、降血压、抗惊厥、抗癫痫、抗氧化、抗衰老、改善微循环等,且安全、无明显毒副作用,其相关制剂在临床上亦被广泛用于心脑血管及神经精神系统疾病,如头痛、冠心病、高血压、后循环缺血性眩晕、突发性耳聋、癫痫、神经衰弱及脑卒中等。考虑到天麻素临床治疗上述疾病常与其他药物或治疗方法联用,故其体内过程及其药代动力学性质不容忽视。目前,有关天麻素综述多集中于药理作用和临床应用方面,而其药代动力学综述鲜见报道。随着天麻素药代动力学研究日渐深入,本研究将从其样品前处理、测定方法、药物ADME过程及影响体内过程的因素等方面较系统全面地对天麻素近年来的药代动力学研究作一综述,以期对天麻素制剂工艺及临床联合配伍应用有所裨益。 相似文献
143.
肺癌是全球发病率和死亡率最高的恶性肿瘤。近年来,随着新型药物的出现和治疗模式的优化,肺癌患者的预后已有一定改善。新辅助治疗是指对潜在可接受手术切除的患者,先给予术前抗肿瘤治疗后再行手术治疗。新辅助治疗通过术前治疗可以缩小肿瘤体积,降低肿瘤分期;并且可以杀灭患者机体中循环肿瘤细胞及微转移病灶,令患者远期生存获益。靶向治疗及免疫治疗已被应用于晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的一线治疗。因此,有临床试验尝试将以上两种治疗手段应用于早期可切除NSCLC患者的新辅助治疗。本文针对新辅助靶向及免疫治疗对早期可切除NSCLC患者的疗效、治疗中的潜在风险予以综述,并探讨新辅助治疗的未来发展方向。 相似文献
144.
145.
146.
147.
Sequential Therapy Based on Evolvement of Patterns: A New Model for Treatment of Alzheimer’s Disease
In order to solve the problem of long-term (>9 months) efficacy in the treatment of Alzheimer''s disease (AD) by conventional therapy (CT), a staged and multiply-targeted sequential therapy based on the evolvement of patterns (STEP) was developed. Its main innovations include: (1) the time order of evolution of patterns defined by Chinese medicine (CM) in AD was found, that is, "the orderly pattern evolution starting from Shen (Kidney) deficiency, progressing to phlegm, stasis and fire, and worsening to severe toxin as well as functional collapse"; (2) the cascade hypothesis of Shen deficiency in AD and its sequential therapy based on Shen-reinforcing was proposed, that is, "reinforcing Shen in the early stage and throughout the whole process, resolving phlegm, activating blood and purging fire in the middle stage, detoxifying and replenishing vitality to stop the collapse in the advanced stage", and through meta-analysis, clinical drug use was optimized, thus the leap from "inferential selection" to "evidence-based selection" was realized; (3) the STEP regimen combined with CT maintained cognitive and behavioral stability in AD patients for at least 12 months, with cognitive enhancement and behavioral synergy after 9 months, and cognitive benefit was superior to CT at 9, 12, 15, 18, 21, and 24 months, respectively. The 2-year cognitive improvement rate was increased by 25.64% (P=0.020) and the cognitive deterioration rate was decreased by 48.71% (P=0.000). Among them, the cognitive and functional benefits of Shen-reinforcing therapy for very early AD (350 cases) for 1 year were better than the placebo (P<0.001), and the dementia conversion rate was reduced by 8.85% (P=0.002). The behavioral symptomatic relief of patients with vascular dementia received fire-purging therapy (540 cases) was superior to those received CT (P=0.016). These data suggested that the STEP regimen has synergistic effects on CTs at least in terms of cognitive benefit, and the earlier the use, the greater the benefit will have. Therefore, the STEP regimen should be considered as one of the clinical options, particularly for the dearth of effective pharmaceutical or immunological interventions that are currently available for AD. 相似文献
148.
目的探讨专科护士-社区护士-个体-家庭四方联动防跌护理模式在社区跌倒高危老年人中的应用与效果。方法选取深圳市龙岗区的2个社区,随机分为观察组和对照组,从两个社区登记建档的跌倒高风险老年居民中分别随机抽选45名进行干预。观察组采用"专科护士-社区护士-个体-家庭"四方联动推进的综合干预方案。对照组接受社区防跌倒常规护理。于干预前及干预后12个月使用修订版社区老年人跌倒危险评估量表、步态和平衡测试量表对两组老年人进行评测,记录两组1年内跌倒发生例次。结果干预期间跌倒发生情况:观察组1人次,对照组6人次。观察组步态和平衡测试得分提高,跌倒危险评估表得分降低,与对照组比较,差异有统计学意义(均P0.01)。结论四方联动的综合干预方案应用于社区居家老年人,能有效降低老年人跌倒风险,提升其防跌能力,对预防社区老年人跌倒的发生有积极作用。 相似文献
149.
150.
The objective of this study was to investigate the absorption behavior of chikusetsusaponin IVa (CHS‐IVa) in the rat intestine using single‐pass intestinal perfusion (SPIP) and to classify CHS‐IVa into the biopharmaceutics classification system (BCS). The equilibrium solubility of CHS‐IVa was determined by the shaker method. The absorption mechanism of CHS‐IVa in the intestine was studied by comparing the Peff of different concentrations of CHS‐IVa. The intestinal site dependence of CHS‐IVa absorption was studied by comparing the Peff of the same concentration of CHS‐IVa in different intestinal segments. The relationship between CHS‐IVa and intestinal efflux protein was studied by perfusion with an efflux protein inhibitor. The permeability of CHS‐IVa was investigated by comparing the Peff of CHS‐IVa and the reported value. The solubility of CHS‐IVa over the pH range 1.0–7.5 was 14.4 ± 0.29 to 16.9 ± 0.34 mg/ml. The Peff of CHS‐IVa in the duodenum was 1.76 × 10?3 to 2.00 × 10?3 cm/min. The Peff of CHS‐IVa in the jejunum was 1.26 × 10?3 to 1.39 × 10?3 cm/min. The Peff of CHS‐IVa in the ileum was 1.25 × 10?3 to 1.31 × 10?3 cm/min. The Peff of CHS‐IVa in the colon was 1.02 × 10?3 to 1.08 × 10?3 cm/min. There was no statistical difference of the Peff in the four segments at different CHS‐IVa concentrations. The Peff of CHS‐IVa (0.07, 0.7 and 7.0 mg/ml) were all notably smaller than the reported Peff (3.00 × 10?3 cm/min) in the jejunum. The Peff of CHS‐IVa was not influenced by verapamil (P‐gp inhibitor), indomethacin (MRP inhibitor) and pantoprazole (BCRP inhibitor). CHS‐IVa was classified as high solubility, low permeability and BCS III. The main absorptive tracts were the upper intestinal tracts and the rank order of intestinal permeability was duodenum > jejunum ≈ ileum > colon. The transport mechanism of CHS‐IVa in all intestinal segments might be primarily passive transport. CHS‐IVa was not a substrate of P‐gp, MRP and BCRP. 相似文献